Generic Valcyte Receives Approval

Article

Aurobindo Pharma Limited has received final approval from the FDA to launch valganciclovir tablets USP, 450 mg, which are therapeutically equivalent to Hoofman-LaRoche's Valcyte.

Aurobindo Pharma Limited has received final approval from the FDA to launch valganciclovir tablets USP, 450 mg, which are therapeutically equivalent to Hoofman-LaRoche’s Valcyte.

The antiviral is designed to treat cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome. It may also be used to prevent CMV disease in patients with kidney, heart, or kidney-pancreas transplants who are at high risk.

For the fiscal year ending in February 2016, the treatment had a market worth of $390.6 million, according to IMS.

Some adverse effects associated with Valcyte include diarrhea, nausea, vomiting, tremors, low blood cell counts, rejection of the transplanted organ, and fever.

Patients on Valcyte may also have a heightened chance of developing cancer or giving birth to children with defects. Valcyte may also lower sperm count and affect fertility in both men and women.

Related Videos
Rear view of Audience listening Speakers on the stage in the conference hall or seminar meeting, business and education about investment concept -  Image credit: THANANIT | stock.adobe.com
Pharmacist helping patient use glucose monitor -- Image credit: Kalyakan | stock.adobe.com
Pride flags during pride event -- Image credit: ink drop | stock.adobe.com
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
selling mental health medication to man at pharmacy | Image Credit: Syda Productions - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.